In vivo antibody diversification targeting a conserved coronavirus epitope
Journal of Experimental Medicine · 2025
DOI: 10.1084/jem.20241563 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Experimental Medicine, 2025. Verfasst von Usha Nair und 14 weiteren Autor:innen. Beteiligte Einrichtung: The Ragon Institute of Mass General, MIT, and Harvard , Cambridge, MA, USA. Hauptthemen laut MEDLINE: SARS-CoV-2, Antibodies, Viral, Epitopes, Antibodies, Monoclonal. Die Arbeit nennt 67 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Massachusetts Consortium on Pathogen Readiness, Gates Foundation, DOE Office of Biological and Environmental Research.
Abstract (Originalsprache)
To explore the use of human B cell receptor (BCR) knock-in mice for broadening antibody responses, we diversified CR3022, a monoclonal antibody (mAb) originally identified in a 2003 severe acute respiratory syndrome coronavirus (SARS-CoV) convalescent patient. This mAb targets a conserved epitope on the coronavirus receptor-binding domain (RBD). We took advantage of high- and low-affinity CR3022 BCR knock-in mice and immunized them with SARS-CoV-2 Wuhan RBD trimers to expand the breadth of these antibodies toward this virus. The resulting antibodies retained the ability to neutralize SARS-CoV and exhibited enhanced affinity and neutralization against the SARS-CoV-2 WA1/2020 strain, as well as the Delta (B.1.617.2) and Omicron KP.3 variants. They also showed broadened reactivity to two bat coronaviruses: WIV1 and, to a lesser potency, BtKY72. Structural analysis revealed key mutations that enhanced binding and neutralization, highlighting the importance of epitope accessibility and variant-specific conformations in antibody diversification. These findings demonstrate that human BCR-expressing mouse models can generate effective antibodies with broad neutralizing activity against viral epitopes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- The Ragon Institute of Mass General, MIT, and Harvard , Cambridge, MA, USA.
- Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.
- Division of Gastroenterology, Massachusetts General Hospital, Boston, MA, USA.
- The Skaggs Institute for Chemical Biology, The Scripps Research Institute , La Jolla, CA, USA.
- Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA.
ORCID-Profile: Usha Nair, Ziqi Feng, Madhav Akauliya, Abigail G Esposito, Charles R Crain, Edward D Lamperti, Thavaleak Prum, John E Warner, Lisa Madungwe, Gordon A Dale, Julie Boucau, Gaurav D Gaiha, Meng Yuan, Ian A Wilson, Facundo D Batista
Förderung
- Massachusetts Consortium on Pathogen Readiness
- Gates Foundation
- DOE Office of Biological and Environmental Research
- NIH HHS
- NIGMS NIH HHS
- Ragon Institute of Mass General, MIT and Harvard
- NIAID NIH HHS
- National Institutes of Health
Zitieren
APA
Nair, U., Feng, Z., Akauliya, M., Esposito, A. G., Crain, C. R., Lamperti, E. D., Prum, T., Warner, J. E., Madungwe, L., Dale, G. A., Boucau, J., Gaiha, G. D., Yuan, M., Wilson, I. A., & Batista, F. D. (2025). In vivo antibody diversification targeting a conserved coronavirus epitope. Journal of Experimental Medicine. https://doi.org/10.1084/jem.20241563
Vancouver
Nair U, Feng Z, Akauliya M, Esposito AG, Crain CR, Lamperti ED, et al. In vivo antibody diversification targeting a conserved coronavirus epitope. Journal of Experimental Medicine. 2025. doi:10.1084/jem.20241563
BibTeX
@article{Nair2025,
author = {Nair, Usha and Feng, Ziqi and Akauliya, Madhav and Esposito, Abigail G and Crain, Charles R and Lamperti, Edward D and Prum, Thavaleak and Warner, John E and Madungwe, Lisa and Dale, Gordon A and Boucau, Julie and Gaiha, Gaurav D and Yuan, Meng and Wilson, Ian A and Batista, Facundo D},
title = {In vivo antibody diversification targeting a conserved coronavirus epitope},
journal = {Journal of Experimental Medicine},
year = {2025},
doi = {10.1084/jem.20241563}
}
EUVIMED